Samsung enters agreement on manufacture of antibody cancer drug

Published: 19-Sep-2023

Building on their existing manufacturing agreement, Bristol Myers Squibb and Samsung Biologics have announced an agreement for large-scale manufacture of a Bristol Myers Squibb commercial antibody cancer drug substance

Samsung Biologics has announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.

Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the strategic relationship over time. 

Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody cancer drug substance at the company’s latest and largest biomanufacturing facility, Plant 4, in Songdo, South Korea. 

This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply

- John Rim, President and CEO of Samsung Biologics

“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” said John Rim, President and CEO of Samsung Biologics. 

“This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity,” continued Rim. 

Samsung Biologics is a fully integrated, end-to-end CDMO service provider, offering development and manufacturing solutions from cell line development to final aseptic fill/finish.

Trending Articles

You may also like